Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-12-16 9:02 pm Unchanged | 13D | Lyra Therapeutics Inc. LYRA | PERCEPTIVE ADVISORS LLC | 12,757,562 19.500% | 0 (Unchanged) | View |
| 2024-11-14 7:48 pm Sale | 13G | Lyra Therapeutics Inc. LYRA | Point72 Asset Management L.P. | 0 0.000% | -3,030,283 (Position Closed) | View |
| 2024-11-14 5:49 pm Sale | 13G | Lyra Therapeutics Inc. LYRA | Venrock Healthcare Capital Partners II L.P. | 1,204,094 1.800% | -4,349,458 (-78.32%) | View |
| 2024-11-14 5:48 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | Samsara BioCapital L.P. | 3,281,766 4.980% | 501,505 (+18.04%) | View |
| 2024-11-14 12:00 pm Sale | 13G | Lyra Therapeutics Inc. LYRA | Vestal Point Capital LP | 0 0.000% | -3,000,000 (Position Closed) | View |
| 2024-08-15 6:31 pm Sale | 13D | Lyra Therapeutics Inc. LYRA | PERCEPTIVE ADVISORS LLC | 12,757,562 19.500% | -1 (-0.00%) | View |
| 2024-02-15 09:18 am Sale | 13G | Lyra Therapeutics Inc. LYRA | PURA VIDA INVESTMENTS LLC | 1,613,844 3.060% | -543,454 (-25.19%) | View |
| 2024-02-14 8:35 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | Venrock Healthcare Capital Partners II L.P. | 5,553,552 9.999% | 2,120,284 (+61.76%) | View |
| 2024-02-14 6:18 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | CITADEL ADVISORS LLC | 4,286,927 7.900% | 1,390,392 (+48.00%) | View |
| 2024-02-14 4:51 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | Nantahala Capital Management LLC | 4,752,324 8.900% | 2,531,494 (+113.99%) | View |
| 2024-02-14 4:29 pm Unchanged | 13D | Lyra Therapeutics Inc. LYRA | PERCEPTIVE ADVISORS LLC | 12,757,563 24.300% | 0 (Unchanged) | View |
| 2024-02-14 4:18 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | Point72 Asset Management L.P. | 3,030,283 5.800% | 30,283 (+1.01%) | View |
| 2024-02-13 4:34 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | Vestal Point Capital LP | 3,000,000 5.700% | 3,000,000 (New Position) | View |
| 2023-11-16 5:00 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | Point72 Asset Management L.P. | 3,000,000 5.400% | 3,000,000 (New Position) | View |
| 2023-08-25 4:15 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | Samsara BioCapital L.P. | 2,780,261 5.600% | 2,780,261 (New Position) | View |
| 2023-06-12 5:23 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | CITADEL ADVISORS LLC | 2,896,535 5.900% | 2,896,535 (New Position) | View |
| 2023-06-09 4:20 pm Purchase | 13D | Lyra Therapeutics Inc. LYRA | NBVM GP LLC | 6,031,468 12.200% | 1,812,666 (+42.97%) | View |
| 2023-06-02 4:16 pm Purchase | 13D | Lyra Therapeutics Inc. LYRA | PERCEPTIVE ADVISORS LLC | 12,757,563 25.800% | 3,610,832 (+39.48%) | View |
| 2023-02-14 4:48 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | Nantahala Capital Management LLC | 2,220,830 7.000% | 2,220,830 (New Position) | View |
| 2023-02-14 4:40 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | Venrock Healthcare Capital Partners II L.P. | 3,433,268 9.999% | 218 (+0.01%) | View |